Cannabidivarin

Source: Wikipedia, the free encyclopedia.
Cannabidivarin
Clinical data
ATC code
  • none
Identifiers
  • 2-((1S,6S)-3-methyl-6-(prop-1-en-2-yl)
    cyclohex-2-enyl)-5-propylbenzene-1,3-diol
JSmol)
  • C=C(C)[C@H]2CCC(\C)=C/[C@@H]2c1c(O)cc(CCC)cc1O
  • InChI=1S/C19H26O2/c1-5-6-14-10-17(20)19(18(21)11-14)16-9-13(4)7-8-15(16)12(2)3/h9-11,15-16,20-21H,2,5-8H2,1,3-4H3/t15-,16+/m1/s1 checkY
  • Key:REOZWEGFPHTFEI-CVEARBPZSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Cannabidivarin (CBDV, GWP42006) is a non-intoxicating

homolog (chemistry) of cannabidiol (CBD), with the side-chain shortened by two methylene bridges
(CH2 units).

Although cannabidivarin (CBDV) is usually a minor constituent of the cannabinoid profile, enhanced levels of CBDV have been reported in feral populations of C. indica ( = C. sativa ssp. indica var. kafiristanica) from northwest India, and in hashish from Nepal.[1]=[2][3]

CBDV demonstrated anticonvulsant in rodent models in a single published study.[4] It was identified for the first time in 1969 by Vollner et al.[5]

Similarly to CBD, it has seven double bond isomers and 30 stereoisomers (see: Cannabidiol#Isomerism). It is not scheduled by Convention on Psychotropic Substances. It is being actively developed by GW Pharmaceuticals (as GWP42006)[6] because of a demonstrated neurochemical pathway for previously observed anti-epileptic and anti-convulsive action.[7] GW has begun several Phase-2 trials for adult epilepsy,[8] for childhood epilepsy and for Prader-Willi Syndrome.[9][10]

See also

References

  1. S2CID 83483599
    .
  2. PMID 21653452
    .
  3. S2CID 4219797
    .
  4. PMID 22970845
    .
  5. PMID 5778489
    .
  6. ^ "GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006". GW Pharmaceuticals. 21 February 2018. Retrieved 28 May 2019.
  7. PMID 24282673
    .
  8. ^ "GW Pharmaceuticals Initiates Phase 2 Clinical Study of Cannabidivarin (CBDV) in Epilepsy" (Press release). GW Pharmaceuticals. May 6, 2015. Retrieved November 10, 2015.
  9. ^ "GW Pharma Press release". Archived from the original on 2015-11-21.
  10. ^ "NSW advice to practitioners on Medical Cannabis trials" (PDF). Archived from the original (PDF) on 2015-11-21.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Cannabidivarin&oldid=1226042234"